Viscoelastic and thermal properties of doxycycline hyclate-loaded bleached shellac in situ -forming gel and –microparticle

2018 ◽  
Vol 44 ◽  
pp. 448-456 ◽  
Author(s):  
Thawatchai Phaechamud ◽  
Nutdanai Lertsuphotvanit ◽  
Pitsiree Praphanwittaya
Keyword(s):  
Thermal Properties ◽  
Doxycycline Hyclate ◽  
In Situ Forming ◽  
In Situ Forming Gel ◽  
Bleached Shellac

Emerging role of polyethylene glycol on doxycycline hyclate-incorporated Eudragit RS in situ forming gel for periodontitis treatment

2019 ◽  
Vol 50 (1) ◽  
pp. 81-94 ◽  
Author(s):  
Wai Wai Lwin ◽  
Napaphol Puyathorn ◽  
Setthapong Senarat ◽  
Jongjan Mahadlek ◽  
Thawatchai Phaechamud
Keyword(s):  
Polyethylene Glycol ◽  
Doxycycline Hyclate ◽  
Eudragit Rs ◽  
In Situ Forming ◽  
In Situ Forming Gel

Injectable in-situ Forming Depot Of Doxycycline Hyclate/α-Cyclodextrin Complex using PLGA for Periodontitis Treatment: Preparation, Charac-terization, and In-Vitro Evaluation

2020 ◽  
Vol 17 ◽  
Author(s):  
Elham Khodaverdi ◽  
Farhad Eisvand ◽  
Mohammad Sina Nezami ◽  
Seyedeh Nesa Rezaeian Shiadeh ◽  
Hossein Kamali ◽  
...  
Keyword(s):  
Complex Form ◽  
Docking Studies ◽  
Morphological Properties ◽  
Burst Release ◽  
Cyclodextrin Complex ◽  
Doxycycline Hyclate ◽  
Scanning Calorimetry ◽  
In Situ Forming

Background:: Doxycycline (DOX) is used in treating a bacterial infection, especially for periodontitis treatment. Objective: To reduce irritation of DOX for subgingival administration and increase the chemical stability and against enzy-matic, the complex of α-cyclodextrin with DOX was prepared and loaded into injectable in situ forming implant based on PLGA. Methods:: FTIR, molecular docking studies, X-ray diffraction, and differential scanning calorimetry was performed to char-acterize the DOX/α-cyclodextrin complex. Finally, the in-vitro drug release and modeling, morphological properties, and cellular cytotoxic effects were also evaluated. Results:: The stability of DOX was improved with complex than pure DOX. The main advantage of the complex is the al-most complete release (96.31 ± 2.56 %) of the drug within 14 days of the implant, whereas in the formulation containing the pure DOX and the physical mixture the DOX with α-cyclodextrin release is reached to 70.18 ± 3.61 % and 77.03 ± 3.56 %, respectively. This trend is due to elevate of DOX stability in the DOX/ α-cyclodextrin complex form within PLGA implant that confirmed by the results of stability. Conclusion:: Our results were indicative that the formulation containing DOX/α-cyclodextrin complex was biocompatible and sustained-release with minimum initial burst release.

Sign in / Sign up

Export Citation Format

Share Document